Clinical Trial Update: A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ABP 959 versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• ABP 959 (ABP 959)
• Eculizumab (eculizumab)

Snippet

Sponsor: Amgen | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Status: COMPLETED | Results posted: 2023-05-23